Literature DB >> 7527823

The growth response to IL-7 during normal human B cell ontogeny is restricted to B-lineage cells expressing CD34.

B N Dittel1, T W LeBien.   

Abstract

The growth of human B cell precursors can be supported by bone marrow (BM) stromal cells and IL-7, but the identity of the responding population is unknown. In the current study, we examined the growth characteristics of FACS-purified CD10+/CD34+/cytoplasmic mu- pro-B cells and CD10+/CD34-/cytoplasmic mu+ pre-B cells in an IL-7/BM stromal cell-dependent culture. Our results show that pro-B cells proliferate, whereas pre-B cells do not. Pro-B cell growth was dependent upon direct contact with BM stromal cells, because no growth occurred when pro-B cells were suspended in transwells above a BM stromal cell monolayer in the presence of IL-7. IL-7-stimulated pro-B cells partially differentiated into a pre-B cell population, on the basis of the loss of CD34 and terminal deoxynucleotidyl (TdT) expression, and the acquisition of cytoplasmic mu heavy chains. Examination of platelet endothelial cell adhesion molecule-1/CD31 expression on B cell precursors revealed a bimodal distribution: CD34+ pro-B cells exhibited a high density pattern and CD34- pre-B cells exhibited a low density pattern. The IL-7-induced differentiation of pro-B cells into pre-B cells included a shift from high CD31 to low CD31 expression. Interestingly, pro-B and pre-B cells expressed comparable levels of IL-7R, as determined by flow cytometry, even though pre-B cells were nonresponsive to IL-7 stimulation. Our collective results show that human pro-B cells require both IL-7 and direct contact with BM stromal cells to undergo proliferation and partial differentiation into the pre-B cell stage, whereas pre-B cells are nonresponsive to IL-7 and require other signals for their survival and growth.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7527823

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Perspective on potential clinical applications of recombinant human interleukin-7.

Authors:  Claude Sportès; Ronald E Gress; Crystal L Mackall
Journal:  Ann N Y Acad Sci       Date:  2009-12       Impact factor: 5.691

2.  IL-7R expression and IL-7 signaling confer a distinct phenotype on developing human B-lineage cells.

Authors:  Sonja E Nodland; Magdalena A Berkowska; Anna A Bajer; Nisha Shah; Dick de Ridder; Jacques J M van Dongen; Tucker W LeBien; Menno C van Zelm
Journal:  Blood       Date:  2011-06-16       Impact factor: 22.113

3.  The density of CD10 corresponds to commitment and progression in the human B lymphoid lineage.

Authors:  Michiko Ichii; Kenji Oritani; Takafumi Yokota; Qingzhao Zhang; Karla P Garrett; Yuzuru Kanakura; Paul W Kincade
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

Review 4.  IL-7 in human health and disease.

Authors:  Wangko Lundström; Natasha M Fewkes; Crystal L Mackall
Journal:  Semin Immunol       Date:  2012-03-10       Impact factor: 11.130

5.  IL-7 Dependence in human B lymphopoiesis increases during progression of ontogeny from cord blood to bone marrow.

Authors:  Yasmin Khan Parrish; Ineavely Baez; Terry-Ann Milford; Abigail Benitez; Nicholas Galloway; Jaqueline Willeman Rogerio; Eva Sahakian; Mercy Kagoda; Grace Huang; Qian-Lin Hao; Yazmar Sevilla; Lora W Barsky; Ewa Zielinska; Mary A Price; Nathan R Wall; Sinisa Dovat; Kimberly J Payne
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

6.  Interleukin 7 independent development of human B cells.

Authors:  J A Prieyl; T W LeBien
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

7.  Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.

Authors:  Valerie I Brown; Junjie Fang; Keith Alcorn; Rosalind Barr; Jenny M Kim; Robert Wasserman; Stephan A Grupp
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

8.  Barley as a green factory for the production of functional Flt3 ligand.

Authors:  Lýdur S Erlendsson; Marcus O Muench; Ulf Hellman; Soffía M Hrafnkelsdóttir; Anders Jonsson; Yves Balmer; Einar Mäntylä; Björn L Orvar
Journal:  Biotechnol J       Date:  2010-02       Impact factor: 4.677

9.  Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.

Authors:  Claude Sportès; Rebecca R Babb; Michael C Krumlauf; Frances T Hakim; Seth M Steinberg; Catherine K Chow; Margaret R Brown; Thomas A Fleisher; Pierre Noel; Irina Maric; Maryalice Stetler-Stevenson; Julie Engel; Renaud Buffet; Michel Morre; Robert J Amato; Andrew Pecora; Crystal L Mackall; Ronald E Gress
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

10.  Efficient retroviral transduction of human B-lymphoid and myeloid progenitors: marked inhibition of their growth by the Pax5 transgene.

Authors:  Rieko Sekine; Toshio Kitamura; Takashi Tsuji; Arinobu Tojo
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.